InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Biogen

BIIB Clue Score50
United States Fiscal year ends December CIK 0000875045 Results filed 28 Oct 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

73
Insider
Date
Role
Action
Shares
Price
Amount
Lloyd Minor
4 Aug 2026
Director
Sold on a plan
593
$200.96
$119.17K
Lloyd Minor
3 Aug 2026
Director
Sold on a plan
593
$203.34
$120.58K
Nicole Murphy
12 Feb 2026
Head of Pharm Ops and Tech
Buy
3
$195.04
$585.11
Priya Singhal
9 Feb 2026
Head of Development
Sold on a plan
2,660
$199.83
$531.55K
Priya Singhal
2 Feb 2026
Head of Development
Sold on a plan
748
$179.30
$134.12K
Priya Singhal
2 Sep 2025
Head of Development
Sold on a plan
517
$133.55
$69.05K
Rachid Izzar
8 Jul 2025
Head of Global Product Strat.
Sold on a plan
2,223
$135.00
$300.11K
Priya Singhal
19 May 2025
Head of Development
Sold on a plan
3,806
$126.25
$480.51K
Caroline Dorsa
2 May 2025
Director
Buy
1,235
$122.72
$151.56K
Stephen A Sherwin
7 Mar 2025
Director
Sold on a plan
8,760
$150.02
$1.31M
Priya Singhal
9 Dec 2024
Head of Development
Sold on a plan
110
$157.21
$17.29K
Priya Singhal
3 Sep 2024
Head of Development
Sold on a plan
431
$204.22
$88.02K
Priya Singhal
2 Apr 2024
Head of Development
Sold on a plan
93
$213.09
$19.82K
Priya Singhal
22 Feb 2024
Head of Development
Sold on a plan
262
$221.23
$57.96K
Priya Singhal
16 Feb 2024
Head of Development
Sold after exercise
108
$221.49
$23.92K
Eric K Rowinsky
15 Feb 2024
Director
Buy
455
$222.54
$101.26K
Priya Singhal
12 Feb 2024
Head of Development
Sold on a plan
419
$239.45
$100.33K
Priya Singhal
2 Feb 2024
Head of Development
Sold on a plan
634
$245.93
$155.92K
Priya Singhal
11 Dec 2023
Head of Development
Sold on a plan
110
$248.00
$27.28K
Priya Singhal
5 Sep 2023
Head of Development
Sold on a plan
431
$269.43
$116.12K
Priya Singhal
3 Jul 2023
Head of Development
Sold on a plan
81
$282.87
$22.91K
Ginger Gregory
28 Apr 2023
EVP, Human Resources
Sold on a plan
2,681
$300.00
$804.30K
Priya Singhal
4 Apr 2023
Head of Development
Sold on a plan
91
$277.11
$25.22K
Priya Singhal
28 Mar 2023
Head of Development
Sell
568
$270.06
$153.39K
Ginger Gregory
14 Nov 2022
EVP, Human Resources
Sell
5,610
$300.11
$1.68M
Susan H Alexander
27 Oct 2022
EVP Chief Legal Off & Corp Sec
Sell
5,532
$280.70
$1.55M
Robin Kramer
3 Dec 2021
Chief Accounting Officer
Exercised, kept
265
$223.92
$59.34K
Robin Kramer
3 Dec 2021
Chief Accounting Officer
Exercised, kept
74
$223.92
$16.57K
Rachid Izzar
2 Dec 2021
Head of Alzheimer's Disease
Exercised, kept
372
$228.52
$85.01K
Michael R. McDonnell
1 Sep 2021
EVP, Chief Financial Officer
Exercised, kept
3,324
$338.24
$1.12M
Michael R. McDonnell
1 Sep 2021
EVP, Chief Financial Officer
Exercised, kept
2,681
$338.24
$906.82K
Robin Kramer
1 Jul 2021
Chief Accounting Officer
Exercised, kept
251
$348.92
$87.58K
Chirfi Guindo
7 Jun 2021
Head of Glob Prod Strat & Com
Sell
3,087
$440.00
$1.36M
Alfred Sandrock
7 Jun 2021
Head of Research & Development
Sell
7,672
$440.00
$3.38M
Brian S Posner
4 Jun 2021
Director
Sell
360
$274.17
$98.70K
Jesus B Mantas
9 Feb 2021
Director
Buy
898
$267.00
$239.77K
Michel Vounatsos
30 Nov 2020
Chief Executive Officer
Buy
3,100
$241.31
$748.05K
Alfred Sandrock
4 Nov 2020
EVP, Research & Development
Sell
1,500
$350.00
$525.00K
Stephen A Sherwin
11 Mar 2020
Director
Sold after exercise
270
$295.29
$79.73K
Stephen A Sherwin
11 Mar 2020
Director
Sold after exercise
2,164
$295.22
$638.85K
Brian S Posner
2 Dec 2019
Director
Sell
1,055
$292.35
$308.43K
Alexander J Denner
2 May 2019
Director
Buy indirect
38,000
$231.24
$8.79M
Michel Vounatsos
1 May 2019
Chief Executive Officer
Buy
4,351
$231.48
$1.01M
Alexander J Denner
1 May 2019
Director
Buy indirect
30,000
$229.46
$6.88M
Alexander J Denner
30 Apr 2019
Director
Buy indirect
50,342
$229.25
$11.54M
Robert W Pangia
18 Mar 2019
Director
Sold after exercise
6,114
$328.55
$2.01M
Susan H Alexander
22 Feb 2019
EVP Chief Legal Officer & Sec.
Exercised, kept
6,395
$48.52
$310.29K
Alexander J Denner
1 Feb 2019
Director
Buy indirect
7,000
$328.45
$2.30M
Alexander J Denner
31 Jan 2019
Director
Buy indirect
25,800
$330.52
$8.53M
Alexander J Denner
30 Jan 2019
Director
Buy indirect
30,000
$324.86
$9.75M
Michael D Ehlers
26 Sep 2018
EVP, Research and Development
Sell
1,000
$350.00
$350.00K
Alexander J Denner
25 Apr 2018
Director
Buy indirect
48,000
$269.91
$12.96M
Alfred Sandrock
27 Feb 2018
EVP, Chief Medical Officer
Sell
259
$290.83
$75.32K
Alfred Sandrock
23 Feb 2018
EVP, Chief Medical Officer
Sold after exercise
908
$293.44
$266.44K
Alfred Sandrock
20 Feb 2018
EVP, Chief Medical Officer
Sell
743
$292.00
$216.96K
Alfred Sandrock
15 Feb 2018
EVP, Chief Medical Officer
Sell
1,294
$298.85
$386.71K
Robert W Pangia
9 Jan 2018
Director
Sold after exercise
5,832
$329.65
$1.92M
Michel Vounatsos
29 Dec 2017
Chief Executive Officer
Buy
780
$320.55
$250.03K
Alexander J Denner
29 Nov 2017
Director
Buy indirect
10,000
$319.84
$3.20M
Alexander J Denner
28 Nov 2017
Director
Buy indirect
20,000
$316.12
$6.32M
Susan H Alexander
25 Jul 2017
EVP Chief Legal Corp Svc & Sec
Sell
4,974
$290.01
$1.44M
Susan H Alexander
19 Jul 2017
EVP Chief Legal Corp Svc & Sec
Sell
7,758
$285.00
$2.21M
Brian S Posner
9 Jun 2017
Director
Sell
1,084
$256.31
$277.84K
Michel Vounatsos
1 May 2017
Chief Executive Officer
Buy
1,402
$271.35
$380.43K
Alexander J Denner
27 Apr 2017
Director
Buy indirect
58,858
$278.48
$16.39M
Alexander J Denner
27 Apr 2017
Director
Buy indirect
15,000
$278.58
$4.18M
Paul J Clancy
25 Apr 2017
Executive VP and CFO
Sell
9,892
$290.00
$2.87M
Alfred Sandrock
3 Apr 2017
EVP CMO Neuro & Neurodegenerat
Sell
1,981
$274.08
$542.95K
Paul J Clancy
13 Mar 2017
Executive VP and CFO
Sell
9,891
$291.55
$2.88M
Alfred Sandrock
1 Mar 2017
EVP CMO Neuro & Neurodegenerat
Sell
973
$290.07
$282.24K
Michel Vounatsos
27 Feb 2017
Chief Executive Officer
Buy
1,333
$285.39
$380.42K
Robert W Pangia
9 Jan 2017
Director
Sold after exercise
5,450
$295.39
$1.61M
Adriana Karaboutis
1 Dec 2016
EVP, Tech, Bus. Sol & Corp Aff
Sell
48
$296.53
$14.23K

What was left out

Form 4 filings counted 436
Amendments (4/A) skipped 1
Filings about a different issuer 9
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 19
Sales straight out of an exercise 7
Sales at will 20
Transactions with no price 0
Shares from compensation/vesting 939,117
Sales filed before the plan box existed 19
History held since 3 Oct 2006